ECLIPSE Trial of Cell-Free DNA Blood-Based CRC Screening Test: Expert Overview
William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.
"Approximately 25%-30% of people we recommend get screened for colorectal cancer, are not getting screened. That motivated the search for a different type of test that might be acceptable to those people who aren't currently getting screening as well as the general population," William M. Grady, coauthor of the multisite Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE) clinical trial, said in a new interview with Patient Care Online. The ECLIPSE trial was designed specifically to evaluate the performance of the Shield cell-free DNA blood-based test from biotechnology company Guardant Health for colorectal cancer screening. In the video above, Dr Grady details the rationale, methods, and results of the ECLIPSE study.
Dr Grady is a professor in the public health sciences division at the Fred Hutchinson Cancer Center in Seattle, Washington. Dr Grady is also the Rodger C. Haggitt professor in the division of gastroenterology at the University of Washington School of Medicine.
